These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37545470)

  • 21. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.
    D'Andrea E; Wexler DJ; Kim SC; Paik JM; Alt E; Patorno E
    JAMA Intern Med; 2023 Mar; 183(3):242-254. PubMed ID: 36745425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Left Ventricular Systolic Function After 3 Months of SGLT2 Inhibitor Therapy in Heart Failure Patients with Reduced Ejection Fraction.
    Mustapic I; Bakovic D; Susilovic-Grabovac Z; Borovac JA
    J Cardiovasc Transl Res; 2023 Oct; 16(5):987-998. PubMed ID: 37155137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis.
    Zafeiropoulos S; Farmakis IT; Milioglou I; Doundoulakis I; Gorodeski EZ; Konstantinides SV; Cooper L; Zanos S; Stavrakis S; Giamouzis G; Butler J; Giannakoulas G
    JACC Heart Fail; 2024 Apr; 12(4):616-627. PubMed ID: 37656079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Empagliflozin on Diuretics Reduction in Outpatient Heart Failure Patients.
    Kim SJ; Kim BJ; Im SI; Kim HS; Heo JH
    Int J Heart Fail; 2022 Oct; 4(4):183-192. PubMed ID: 36381017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
    Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
    Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing angiotensin receptor-neprilysin inhibitors with sodium-glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus.
    Tsai ML; Lin Y; Lin MS; Tsai TH; Yang NI; Wang CY; Hsieh IC; Hung MJ; Chen TH
    Diabetol Metab Syndr; 2023 May; 15(1):110. PubMed ID: 37237322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardio-renal-metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort.
    Beles M; Masuy I; Verstreken S; Bartunek J; Dierckx R; Heggermont W; Oeste C; De Boeck M; Fovel I; Maris M; Vermeulen Z; Vanderheyden M
    ESC Heart Fail; 2023 Aug; 10(4):2269-2280. PubMed ID: 37095712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction.
    Kim HM; Hwang IC; Choi W; Yoon YE; Cho GY
    Sci Rep; 2021 Nov; 11(1):22342. PubMed ID: 34785723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
    Fu EL; Patorno E; Everett BM; Vaduganathan M; Solomon SD; Levin R; Schneeweiss S; Desai RJ
    Eur Heart J; 2023 Jun; 44(24):2216-2230. PubMed ID: 37259575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis.
    Zhang N; Wang Y; Tse G; Korantzopoulos P; Letsas KP; Zhang Q; Li G; Lip GYH; Liu T
    Eur J Prev Cardiol; 2022 Feb; 28(17):1961-1973. PubMed ID: 34792124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction of SGLT2 Inhibitors and Variations in Other Disease-Modifying Drugs in Heart Failure Patients: A Single-Centre Real-World Experience.
    Tabella E; Correale M; Alcidi G; Pugliese R; Ioannoni S; Romano M; Palmieri G; Di Biase M; Brunetti ND; Iacoviello M
    Clin Pract; 2023 Aug; 13(5):1015-1024. PubMed ID: 37736926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors.
    Marques P; Matias P; Packer M; Vieira JT; Vasques-Nóvoa F; Sharma A; Mavrakanas TA; Friões F; Ferreira JP
    Eur J Heart Fail; 2023 Dec; 25(12):2191-2198. PubMed ID: 37559543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
    J Am Heart Assoc; 2021 Jun; 10(11):e020237. PubMed ID: 34013739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitor Use in Acute Heart Failure Hospitalizations Complicated by AKI.
    Aklilu AM; Kumar S; Yamamoto Y; Moledina DG; Sinha F; Testani JM; Wilson FP
    Kidney360; 2023 Oct; 4(10):1371-1381. PubMed ID: 37644648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loop diuretic use among patients with heart failure and type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors.
    Weeda ER; Cassarly C; Brinton DL; Shirley DW; Simpson KN
    J Diabetes Complications; 2019 Aug; 33(8):567-571. PubMed ID: 31176543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.
    Pandey AK; Dhingra NK; Hibino M; Gupta V; Verma S
    ESC Heart Fail; 2022 Apr; 9(2):942-946. PubMed ID: 35112512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of sodium-glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics.
    Weng YF; Chen CY; Hwang SJ; Huang YB
    Kaohsiung J Med Sci; 2023 Apr; 39(4):416-425. PubMed ID: 36625282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry.
    Greene SJ; Ezekowitz JA; Anstrom KJ; Demyanenko V; Givertz MM; Piña IL; O'Connor CM; Koglin J; Roessig L; Hernandez AF; Armstrong PW; Mentz RJ
    J Card Fail; 2022 Jul; 28(7):1063-1077. PubMed ID: 35301107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of sodium-glucose cotransporter 2 inhibitors on left atrial remodeling and prognosis in patients with type 2 diabetes and heart failure with reduced ejection fraction.
    Yu S; Sun Y; Wang N; Lv X; Si J; Zhang X; Zhang Y; Liu Y
    J Cardiovasc Med (Hagerstown); 2023 Nov; 24(11):829-837. PubMed ID: 37642649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.